Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous ADMSCs for Primary Knee Osteoarthritis
NCT02544802Phase 1Completed
- Sponsor
- Steminent Biotherapeutics
- Start
- Jun 2015
- Primary completion
- Jan 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous adipose-derived mesenchymal stromal cells in osteoarthritis (OA), sponsored by Steminent Biotherapeutics. Primary endpoint: Safety of intra-articular injection of autologous ADMSCs at 12 months. Started Jun 2015; status: completed.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02544802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02544802.